Basic principles of antisense drug discovery

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 117-141

  Freier, Susan M ^a   Watt, Andrew T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879913488     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. M. L. Stephenson and P. C. Zamecnik; Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide; Proceedings of the National Academy of Science USA; 75; 285-258; 1978.
2. K. V. Prasanth, S. G. Prasanth, Z. Xuan, S. Hearn, S. M. Freier, C. F. Bennett, M. Q. Zhang, and D. L. Spector; Regulating gene expression through RNA nuclear retention; Cell; 123; 249-263; 2005.
3. B. A. Zinker, C. M. Rondinone, J. M. Trevillyan, R. J. Gum, J. E. Clampit, J. F. Waring, N. Xie, D. Wilcox, P. Jacobson, L. Frost, P. E. Kroeger, R. M. Reilly, S. Koterski, T. J. Opgenorth, R. G. Ulrich, S. Crosby, M. Butler, S. F. Murray, R. A. McKay, S. Bhanot, B. P. Monia, and M. R. Jirousek; PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice; Proceedings of the National Academy of Science USA; 99; 11,357-11,362; 2002.
4. S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman; Basic local alignment search tool; J. Mol. Biol.; 215; 403-410; 1990.
5. M. Lutzelberger and J. Kjems; Strategies to identify potential therapeutic target sites in RNA; in: Handbook of Experimental Pharmacology; V. A. Erdmann, J. Brosius, and J. Barciszewski, Eds; Vol. 173; Springer, Berlin, 2006; pp. 243-259.
6. T. A. Vickers, S. Koo, C. F. Bennett, S. T. Crooke, N. M. Dean, and B. F. Baker; Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis; J. Biol. Chem.; 278; 7108-7118; 2003.
7. D. H. Mathews, M. E. Burkard, S. M. Freier, J. R. Wyatt, and D. H. Turner; Predicting oligonucleotide affinity to nucleic acid targets; RNA; 5; 1458-1469; 1999.
8. P. Arrigo, G. Ivaldi, and P. P. Cardo; In silico determination of potential antisense targets for human beta-globin variants; In Silico Biol.; 2; 143-150; 2002.
9. X. Bo, S. Lou, D. Sun, W. Shu, J. Yang, and S. Wang; Selection of antisense oligonucleotides based on multiple predicted target mRNA structures; BMC Bioinformatics; 7; 122; 2006.
10. X. Bo and S. Wang; TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA; Bioinformatics; 21; 1401-1402; 2005.
11. A. M. Chalk and E. L. Sonnhammer; Computational antisense oligo prediction with a neural network model; Bioinformatics; 18; 1567-1575; 2002.
12. R. K. Far, J. Leppert, K. Frank, and G. Sczakiel; Technical improvements in the computational target search for antisense oligonucleotides; Oligonucleotides; 15; 223-233; 2005.
13. M. C. Giddings, A. A. Shah, S. Freier, J. F. Atkins, R. F. Gesteland, and O. V. Matveeva; Artificial neural network prediction of antisense oligodeoxynucleotide activity; Nucleic Acids Res.; 30; 4295-4304; 2002.
14. O. V. Matveeva, D. H. Mathews, A. D. Tsodikov, S. A. Shabalina, R. F. Gesteland, J. F. Atkins, and S. M. Freier; Thermodynamic criteria for high hit rate antisense oligonucleotide design; Nucleic Acids Res.; 31; 4989-4994; 2003.
15. V. Patzel, U. Steidl, R. Kronenwett, R. Haas, and G. Sczakiel; A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability; Nucleic Acids Res.; 27; 4328-4334; 1999.
16. M. Scherr, J. J. Rossi, G. Sczakiel, and V. Patzel; RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts; Nucleic Acids Res.; 28; 2455-2461; 2000.
17. G. Sczakiel; Theoretical and experimental approaches to design effective antisense oligonucleotides; Front. Biosci.; 5; D194-201; 2000.
18. S. A. Shabalina, A. N. Spiridonov, and A. Y. Ogurtsov; Computational models with thermodynamic and composition features improve siRNA design; BMC Bioinformatics; 7; 65; 2006.
19. R. A. Stull, L. A. Taylor, and F. C. Szoka, Jr.; Predicting antisense oligonucleotide inhibitory efficacy:a computational approach using histograms and thermodynamic indices; Nucleic Acids Res.; 20; 3501-3508; 1992.
20. N. Toschi; Influence of mRNA self-structure on hybridization: computational tools for antisense sequence selection; Methods; 22; 261-269; 2000.
21. E. Kierzek, D. H. Mathews, A. Ciesielska, D. H. Turner, and R. Kierzek; Nearest neighbor parameters for Watson-Crick complementary heteroduplexes formed between 2′-O-methyl RNA and RNA oligonucleotides; Nucleic Acids Res.; 34; 3609-3614; 2006.
22. D. H. Mathews; Revolutions in RNA secondary structure prediction; J. Mol. Biol.; 359; 526-532; 2006.
23. D. H. Mathews and D. H. Turner; Prediction of RNA secondary structure by free energy minimization; Curr. Opin. Struct. Biol.; 16; 270-278; 2006.
24. T. A. Vickers, J. R. Wyatt, and S. M. Freier; Effects of RNA secondary structure on cellular antisense activity; Nucleic Acids Res.; 28; 1340-1347; 2000.
25. G. C. Tu, Q. N. Cao, F. Zhou, and Y. Israel; Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design; J. Biol. Chem.; 273; 25,125-25,131; 1998.
26. O. V. Matveeva, A. D. Tsodikov, M. Giddings, S. M. Freier, J. R. Wyatt, A. N. Spiridonov, S. A. Shabalina, R. F. Gesteland, and J. F. Atkins; Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity; Nucleic Acids Res.; 28; 2862-2865; 2000.
27. R. Bakalova, Z. Zhelev, H. Ohba, and Y. Baba; Quantum dot-conjugated hybridization probes for preliminary screening of siRNA sequences; J. Am. Chem. Soc.; 127; 11,328-11,335; 2005.
28. D. J. Ecker, T. A. Vickers, R. Hanecak, V. Driver, and K. Anderson; Rational screening of oligonucleotide combinatorial libraries for drug discovery; Nucleic Acids Res.; 21; 1853-1856; 1993.
29. S. P. Ho, Y. Bao, T. Lesher, R. Malhotra, L. Y. Ma, S. J. Fluharty, and R. R. Sakai; Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries; Nat. Biotechnol.; 16; 59-63; 1998.
30. S. P. Ho, D. H. Britton, Y. Bao, and M. S. Scully; RNA mapping: selection of potent oligonucleotide sequences for antisense experiments; Methods Enzymol.; 314; 168-83; 2000.
31. O. Matveeva, B. Felden, A. Tsodikov, J. Johnston, B. P. Monia, J. F. Atkins, R. F. Gesteland, and S. M. Freier; Prediction of antisense oligonucleotide efficacy by in vitro methods; Nat. Biotechnol.; 16; 1374-1375; 1998.
32. M. Ooms, K. Verhoef, E. Southern, H. Huthoff, and B. Berkhout; Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays; Nucleic Acids Res.; 32; 819-827; 2004.
33. M. Sohail, G. Doran, S. Kang, S. Akhtar, and E. M. Southern; Structural rearrangements in RNA on the binding of an antisense oligonucleotide: implications for the study of intra-molecular RNA interactions and the design of cooperatively acting antisense reagents with enhanced efficacy; J. Drug Target; 13; 61-70; 2005.
34. M. Sohail, H. Hochegger, A. Klotzbucher, R. L. Guellec, T. Hunt, and E. M. Southern; Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo; Nucleic Acids Res.; 29; 2041-2051; 2001.
35. S. P. Walton, G. N. Stephanopoulos, M. L. Yarmush, and C. M. Roth; Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA; Biophys. J.; 82; 366-377; 2002.
36. S. Duan, D. H. Mathews, and D. H. Turner; Interpreting oligonucleotide microarray data to determine RNA secondary structure: application to the 3′ end of Bombyx mori R2 RNA; Biochemistry; 45; 9819-9832; 2006.
37. W. F. Lima, V. Brown-Driver, M. Fox, R. Hanecak, and T. W. Bruice; Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity; J. Biol. Chem.; 272; 626-638; 1997.
38. O. Matveeva, B. Felden, S. Audlin, R. F. Gesteland, and J. F. Atkins; A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures; Nucleic Acids Res.; 25; 5010-5016; 1997.
39. A. M. Krieg; Therapeutic potential of Toll-like receptor 9 activation; Nat. Rev. Drug Discov.; 5; 471-484; 2006.
40. A. M. Krieg, A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman; CpG motifs in bacterial DNA trigger direct B-cell activation; Nature; 374; 546-549; 1995.
41. C. F. Bennett, M. Y. Chiang, L. Wilson-Lingardo, and J. R. Wyatt; Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides; Nucleic Acids Res.; 22; 3202-3209; 1994.
42. W. R. Pearson and D. J. Lipman; Improved tools for biological sequence comparison; Proceedings of the National Academy of Science USA; 85; 2444-2448; 1988.
43. J. C. Wootton and S. Federhen; Analysis of compositionally biased regions in sequence databases; Methods Enzymol.; 266; 554-571; 1996.
44. A. Smit, R. Hubley, and P. Green; RepeatMasker; http://repeatmasker.org; 2006.
45. N. M. Dean, R. McKay, T. P. Condon, and C. F. Bennett; Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters; J. Biol. Chem.; 269; 16,416-16,424; 1994.
46. C. Esau, X. Kang, E. Peralta, E. Hanson, E. G. Marcusson, L. V. Ravichandran, Y. Sun, S. Koo, R. J. Perera, R. Jain, N. M. Dean, S. M. Freier, C. F. Bennett, B. Lollo, and R. Griffey; MicroRNA-143 regulates adipocyte differentiation; J. Biol. Chem.; 279; 52,361-52,365; 2004.
47. W. Wang, H. J. Chen, A. Schwartz, P. J. Cannon, C. A. Stein, and L. E. Rabbani; Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides; J. Clin. Invest.; 98; 443-450; 1996.
48. D. J. Ecker, J. R. Wyatt, T. A. Vickers, R. Buckheit, J. Roberson and J.-L. Imbach; Novel guanosine quartet structure binds to the HIV envelope and inhibits envelope mediated cell fusion; Nucleos. Nucleot.; 14; 1117-1127; 1995.
49. E. W. Ng, D. T. Shima, P. Calias, E. T. Cunningham, Jr., D. R. Guyer, and A. P. Adamis; Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease; Nat. Rev. Drug. Discov.; 5; 123-132; 2006.
50. S. A. Bustin; Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays; J. Mol. Endocrinol.; 25; 169-193; 2000.
51. T. P. Condon and C. F. Bennett; Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells; J. Biol. Chem.; 271; 30,398-30,403; 1996.
52. T. A. Vickers, H. Zhang, M. J. Graham, K. M. Lemonidis, C. Zhao, and N. M. Dean; Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide; J. Immunol.; 176; 3652-3661; 2006.
53. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R. K. Pandey, T. Racie, K. G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, and H. P. Vornlocher; Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs; Nature; 432; 173-178; 2004.
54. L. M. Watts, V. P. Manchem, T. A. Leedom, A. L. Rivard, R. A. McKay, D. Bao, T. Neroladakis, B. P. Monia, D. M. Bodenmiller, J. X. Cao, H. Y. Zhang, A. L. Cox, S. J. Jacobs, M. D. Michael, K. W. Sloop, and S. Bhanot; Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism; Diabetes; 54; 1846-1853; 2005.
55. S. P. Ho, L. K. Takahashi, V. Livanov, K. Spencer, T. Lesher, C. Maciag, M. A. Smith, K. W. Rohrbach, P. R. Hartig, and S. P. Arneric; Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor; Brain Res. Mol. Brain Res.; 89; 29-40; 2001.
56. H. Zhang, J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, and N. M. Dean; Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis; Nat. Biotechnol.; 18; 862-867; 2000.